The estimated Net Worth of Daryl Faulkner is at least $3.05 millió dollars as of 29 April 2020. Mr. Faulkner owns over 14,450 units of GenMark Diagnostics Inc stock worth over $2,890,522 and over the last 14 years he sold GNMK stock worth over $0. In addition, he makes $156,402 as Independent Director at GenMark Diagnostics Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Faulkner GNMK stock SEC Form 4 insiders trading
Daryl has made over 3 trades of the GenMark Diagnostics Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 14,450 units of GNMK stock worth $86,700 on 29 April 2020.
The largest trade he's ever made was exercising 14,450 units of GenMark Diagnostics Inc stock on 29 April 2020 worth over $86,700. On average, Daryl trades about 1,379 units every 168 days since 2010. As of 29 April 2020 he still owns at least 120,238 units of GenMark Diagnostics Inc stock.
You can see the complete history of Mr. Faulkner stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Daryl Faulkner biography
Daryl Jay Faulkner serves as Independent Director of the Company. Mr. Faulkner has 35 years of experience in medical devices, molecular tools and reagents, and molecular diagnostics. Mr. Faulkner was initially appointed to the board of directors of Osmetech, plc (the predecessor to GenMark Diagnostics, Inc.) in August 2008, serving as Non-Executive Chairman until December 2008. Mr. Faulkner served as Executive Chair and Interim Chief Executive Officer of Aspen Bio Pharma from February 2009 until March 2010. Mr. Faulkner served as President and Chief Executive Officer and as a Director of Digene Corp., a developer of gene-based diagnostic tests, from December 2006 until consummation of Qiagen NV’s acquisition of Digene in August 2007. From August 2008 to January 2009, Mr. Faulkner served as a consultant to Qiagen, in connection with its post-acquisition integration of Digene. From 1998 until March 2006, Mr. Faulkner served in several executive roles at Life Technologies, Inc. and Invitrogen Corp., both life sciences companies, including SVP and General Manager of Europe, SVP, International Operations, and SVP, Strategic Business Units. Mr. Faulkner received a B.S. in Industrial Relations from the University of North Carolina, Chapel Hill and an M.A. in Business Management from Webster University.
What is the salary of Daryl Faulkner?
As the Independent Director of GenMark Diagnostics Inc, the total compensation of Daryl Faulkner at GenMark Diagnostics Inc is $156,402. There are 7 executives at GenMark Diagnostics Inc getting paid more, with Scott Mendel having the highest compensation of $1,749,300.
How old is Daryl Faulkner?
Daryl Faulkner is 71, he's been the Independent Director of GenMark Diagnostics Inc since 2010. There are no older and 9 younger executives at GenMark Diagnostics Inc.
Insiders trading at GenMark Diagnostics Inc
Over the last 14 years, insiders at GenMark Diagnostics Inc have traded over $27,572,889 worth of GenMark Diagnostics Inc stock and bought 454,838 units worth $2,182,328 . The most active insiders traders include Hany Massarany, Jon Faiz Kayyem és Kevin C Oboyle. On average, GenMark Diagnostics Inc executives and independent directors trade stock every 5 days with the average trade being worth of $141,403. The most recent stock trade was executed by Michael Gleeson on 14 April 2021, trading 27,667 units of GNMK stock currently worth $326,471.
What does GenMark Diagnostics Inc's logo look like?
Complete history of Mr. Faulkner stock trades at GenMark Diagnostics Inc
GenMark Diagnostics Inc executives and stock owners
GenMark Diagnostics Inc executives and other stock owners filed with the SEC include:
-
Scott Mendel,
President, Chief Executive Officer, Director -
Johnny Ek,
Chief Financial Officer -
Michael Gleeson,
Senior Vice President, Corporate Accounts -
Eric Stier,
Senior Vice President, General Counsel, Secretary -
James Fox,
Non-Executive Independent Director -
Kevin O'Boyle,
Independent Chairman of the Board -
Lisa Giles,
Independent Director -
Daryl Faulkner,
Independent Director -
Michael Kagnoff,
Independent Director -
Tyler Jensen,
Senior Vice President - Engineering and Product Technical Support -
Jon Faiz Kayyem,
President & CEO -
Jennifer Anne Williams,
SVP Global Operations -
Wade R. Stevenson,
SVP, North America Sales -
Brian Andrew Mitchell,
SVP, Operations -
Christine Shaw,
VP, Assay Development -
John Frederick Ek,
Chief Financial Officer -
Richard B Slansky,
Chief Financial Officer -
Stephen T Worland,
Director -
Jeffrey Alan Hawkins,
SVP, Marketing & Bus Dev -
Ingo Chakravarty,
SVP, International -
Christopher M Gleeson,
Director -
James B. Mc Nally,
SVP, Marketing and Bus. Dev. -
Jorge Garces,
SVP, Research & Development -
Paul Ross,
CFO & Secretary -
Pankaj Singhal,
Sr. VP, Product Dev & Mftg -
Matthew Robert Cohen,
SVP, Gen Counsel & Secretary -
John Bellano,
SR. VP, Commercial Operations -
Steven J Kemper,
CFO, Treasurer & Secretary -
Bradley Calvin,
Senior VP, Global Marketing -
Scott Alexander O'brien,
SVP, Global Mktg & Int'l Sales -
Hany Massarany,
President and CEO -
Sarah Hollis Winkler,
VP, Human Resources -
Alan Baer Maderazo,
VP, Qual, Reg, & Clin Affairs -
Michael John Harkins,
SVP, Sales -
Abdul Chohan,
SVP Operations